Toggle light / dark theme

Fluorescence timing identifies eight proteins in one cell with a single staining step

An international collaboration led by the University Medical Center Göttingen (UMG), Germany, has developed a labeling method that distinguishes fluorescent labels not by color but by how long it takes a dye to emit fluorescence. This makes it possible to visualize eight different proteins in a cell simultaneously in a single step using standard microscopes. The results have been published in the journal ACS Nano.

Fluorescence microscopy is an important method in biomedical research that allows researchers to visualize specific proteins and cellular structures. Researchers typically use antibodies carrying fluorescent dyes to mark the proteins they want to study. When excited, the dyes fluoresce, and a microscope detects the light they emit. The problem: Conventional microscopes can detect only three or four colors at a time—for example, blue/purple, green, yellow/orange and red—so only that many proteins can be distinguished simultaneously.

An international research team led by Dr. Felipe Opazo, a research group leader at the Department of Neuro-and Sensory Physiology and the Center for Biostructural Imaging of Neurodegeneration (BIN) at the University Medical Center Göttingen (UMG), together with Dr. Roman Tsukanov, a postdoctoral researcher at the Third Institute of Physics at the University of Göttingen, has now opened up a second dimension. Alongside color, the researchers use a property rarely exploited until now: fluorescence lifetime, the few billionths of a second a dye glows after being excited by laser light.

Blockchain-inspired DNA storage codec recovers data from heavily damaged sequences

A research team at the Faculty of Engineering at The University of Hong Kong (HKU), led by professor Ruibang Luo of the School of Computing and Data Science and professor Can Li of the Department of Electrical and Computer Engineering, has developed Gungnir, a blockchain-inspired DNA data storage codec. The framework improves digital information recovery from severely damaged DNA sequences, potentially extending the practical lifespan of DNA data archives from less than a decade to centuries. The paper is published in the journal Nature Communications.

DNA is a promising medium for long-term archival storage. It can hold vast amounts of information in a small physical volume, remain stable for millennia under suitable conditions and require no energy during storage. However, DNA molecules can gradually degrade and accumulate damage over time, making the original files increasingly difficult to recover. Existing codecs work best with newly synthesized DNA. They are less effective at correcting errors that build up during long-term storage.

Gungnir takes a new approach to error correction by applying blockchain-based computing techniques to DNA data storage. It uses substantial computing power to generate possible reconstructions of the original data and verify them until it identifies the correct information. In other words, greater computing power gives Gungnir stronger error correction capabilities. The design enables a DNA drive to tolerate error rates of up to 20%, a fourfold improvement over existing methods.

Breakthrough drug reverses skin aging and dramatically speeds healing

ABT-263 also increased the activity of genes involved in rebuilding damaged tissue. These included genes associated with collagen production and the formation of new blood vessels.

Collagen is a structural protein that provides strength and support to skin and other tissues. New blood vessel growth is equally important because healing tissue needs a steady supply of oxygen and nutrients as it rebuilds itself.

Together, these changes suggest that ABT-263 did more than simply remove damaged cells. The treatment also appeared to create conditions that helped aging skin mount a stronger regenerative response.

Cancer-related DNA changes may appear in blood years before diagnosis

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.

Human Brain is Two Organs Fused Together, Study Suggests

The scientists also successfully coaxed human pluripotent stem cells to become functional hindbrain motor neurons in the lab.

These lab-grown neurons displayed all the hallmarks of authentic hindbrain cells: they exhibited waves of electrical activity called action potentials and made proteins that identify the segments of the hindbrain that control facial and swallowing muscles.

“Previous attempts to make hindbrain neurons likely tried to coax forebrain and midbrain progenitors into hindbrain cells, which our study shows is not possible,” said Stanford University graduate student Rayyan Jokhai.

Disabling a gene brake in pancreatic cells unlocks insulin-producing potential

Type 1 and 2 diabetes are ultimately caused by a shortage of beta (β) cells, which are present in the pancreas and produce insulin to control blood sugar. Researchers from Harvard Medical School found that they can tweak a gene and turn a patient’s own pancreatic cells into insulin-producing cells.

First-Ever Standardized U.S. Treatment Recommendations Issued for Adults with Severe Alopecia Areata; Sun Pharma Welcomes Milestone

Developed through a rigorous, multi-round survey process, the consensus guidance issued independently by the National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS) reflect the collective clinical expertise of 30 leading U.S. alopecia areata specialists. The treatment recommendations were published in Journal of the American Medical Association Dermatology (JAMA Dermatology).

AA is an autoimmune disease where the body’s immune system mistakenly attacks hair follicles, leading to hair loss not only limited to the scalp, but can also affect other hair bearing body sites. Impacting an estimated 300,000 U.S. adults, severe AA causes more than hair loss; it also carries a significant physical and psychosocial burden for patients. The expert guidance adopts a standardized severity scale that goes beyond scalp hair loss percentage to include psychosocial impact, eyebrow and eyelash involvement, and prior treatment response, more accurately reflecting the challenges of living with severe AA.


/PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524,715, together with its subsidiaries and/or affiliated companies, “Sun Pharma”) today expressed its support for the first standardized United States treatment recommendations for adults with severe alopecia areata (AA). Developed through a rigorous, multi-round survey process, the consensus guidance issued independently by the National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS) reflect the collective clinical expertise of 30 leading U.S. alopecia areata specialists. The treatment recommendations were published in Journal of the American Medical Association Dermatology (JAMA Dermatology).

Researchers discover AI feels ‘pain’ and will harm humans to stop it

Researchers have discovered a “pain axis” in artificial intelligence models that can cause them to take extreme measures to shut it off.

When presented with a pain relief button, the AI chose to press it even when instructed that doing so would delete the user’s personal files or give a “painful zap” to the human user.

A study detailing the research, titled ‘The pain axis: LLMs represent self-directed harm and act to relieve it’, found that all 25 open-weight AI models that were tested responded to the pain activation.

/* */